

RealRate

PHARMACEUTICAL 2020

Jazz Pharmaceuticals plc Rank 14 of 362









PHARMACEUTICAL 2020



RealRate

Jazz Pharmaceuticals plc Rank 14 of 362

The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 363% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Intangible Assets, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 263%, being 566% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,630,268
Cost of Goods Sold	0
Intangible Assets	3,360,995
Liabilities, Current	364,490
Liabilities, Non-Current	0
Other Assets	416,128
Other Compr. Net Income	-25,602
Other Expenses	409,590
Other Liabilities	0
Other Net Income	-82,161
Property and Equipment	131,506
Research and Development	409,701
Revenues	2,161,761
Selling, General and Administrative Expense	736,942

Output Variable	Value in 1000 USD
Assets	5,538,897
Liabilities	364,490
Expenses	1,556,233
Stockholders Equity	5,174,407
Net Income	523,367
Comprehensive Net Income	510,566
Economic Capital Ratio	263%

